RPRX Royalty Pharma plc Stock Quote

RPRX [NASD]

Index	-	P/E	24.67	EPS (ttm)	1.49	Insider Own	0.20%	Shs Outstand	383.99M	Perf Week	-4.65%
Market Cap	22.34B	Forward P/E	11.96	EPS next Y	3.07	Insider Trans	-69.67%	Shs Float	176.77M	Perf Month	-11.64%
Income	564.30M	PEG	3.08	EPS next Q	0.69	Inst Own	62.80%	Short Float	5.75%	Perf Quarter	-12.13%
Sales	2.19B	P/S	10.18	EPS this Y	-66.60%	Inst Trans	4.66%	Short Ratio	4.62	Perf Half Y	-23.63%
Book/sh	12.71	P/B	2.89	EPS next Y	11.55%	ROA	3.50%	Target Price	52.71	Perf Year	-14.95%
Cash/sh	3.90	P/C	9.43	EPS next 5Y	8.00%	ROE	12.30%	52W Range	34.80 - 53.23	Perf YTD	-26.59%
Dividend	0.68	P/FCF	-	EPS past 5Y	-	ROI	14.70%	52W High	-30.98%	Beta	-
Dividend %	1.85%	Quick Ratio	9.40	Sales past 5Y	-	Gross Margin	-	52W Low	5.57%	ATR	1.06
Employees	51	Current Ratio	9.40	Sales Q/Q	14.40%	Oper. Margin	65.30%	RSI (14)	28.29	Volatility	2.84% 2.56%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-3.00%	Profit Margin	25.70%	Rel Volume	0.93	Prev Close	37.68
Shortable	Yes	LT Debt/Eq	1.19	Earnings	Aug 11 BMO	Payout	31.60%	Avg Volume	2.20M	Price	36.74
Recom	2.40	SMA20	-8.38%	SMA50	-12.13%	SMA200	-15.89%	Volume	2,038,486	Change	-2.49%

Jul-30-21

Initiated

Tigress Financial

Buy

$50

Nov-09-20

Upgrade

UBS

Neutral → Buy

$52 → $51

Jul-14-20

Initiated

Evercore ISI

In-line

Jul-13-20

Initiated

UBS

Neutral

$52

Jul-13-20

Initiated

SunTrust

Buy

$56

Jul-13-20

Initiated

Morgan Stanley

Equal-Weight

$51

Jul-13-20

Initiated

JP Morgan

Neutral

$50

Jul-13-20

Initiated

Goldman

Neutral

$47

Jul-13-20

Initiated

Cowen

Outperform

$55

Jul-13-20

Initiated

Citigroup

Neutral

$50

Jul-13-20

Initiated

BofA Securities

Buy

$55

Jul-29-21 07:02AM	What Type Of Shareholders Own The Most Number of Royalty Pharma plc (NASDAQ:RPRX) Shares? Simply Wall St.
Jul-19-21 09:00AM	Royalty Pharma to Announce Second-Quarter 2021 Financial Results on August 11, 2021 GlobeNewswire
Jul-16-21 09:00AM	Royalty Pharma Declares Third-Quarter 2021 Dividend GlobeNewswire
Jul-15-21 04:54PM	Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond GlobeNewswire
Jul-13-21 10:41AM	Hedge Funds Are Crazy About Royalty Pharma Plc (RPRX) Insider Monkey
Jul-05-21 05:30AM	Midsize Pharmaceutical Firms Are the Industrys Big Deal Makers This Year The Wall Street Journal
Jun-07-21 09:00AM	Royalty Pharma to Present at Upcoming Investor Conferences GlobeNewswire
Jun-02-21 07:40AM	Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys GlobeNewswire +6.68%
May-18-21 08:49AM	Declining Stock and Decent Financials: Is The Market Wrong About Royalty Pharma plc (NASDAQ:RPRX)? Simply Wall St.
May-11-21 08:00PM	Repros Therapeutics (RPRX) Q1 2021 Earnings Call Transcript Motley Fool
07:00AM	Royalty Pharma Reports First Quarter 2021 Results GlobeNewswire
05:45AM	Royalty Pharma plc - Ordinary Shares - Class A to Host Earnings Call ACCESSWIRE
May-07-21 09:00AM	Royalty Pharma to Present at Upcoming Investor Conferences GlobeNewswire
Apr-21-21 04:15PM	Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021 GlobeNewswire
08:10AM	Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes GlobeNewswire
Apr-15-21 09:00AM	Royalty Pharma Declares Second-Quarter 2021 Dividend GlobeNewswire
Apr-08-21 07:40AM	Royalty Pharma Acquires OXLUMO Royalty Interest From Dicerna for up to $240 Million GlobeNewswire
07:30AM	Dicerna Sells OXLUMO (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million Business Wire
Apr-01-21 07:30AM	Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK GlobeNewswire
Mar-30-21 08:00AM	Royalty Pharma Appoints Henry A. Fernandez as Lead Independent Director GlobeNewswire
Mar-11-21 02:37PM	Spot Emerging Growth Stocks Like Upstart, Fiserv By Following The Smart Money Investor's Business Daily
Feb-17-21 12:30PM	Repros Therapeutics (RPRX) Q4 2020 Earnings Call Transcript Motley Fool
07:00AM	Royalty Pharma Reports Q4 2020 and Full-Year Results GlobeNewswire
05:45AM	Royalty Pharma plc - Ordinary Shares - Class A to Host Earnings Call ACCESSWIRE
Feb-15-21 05:30AM	Is Royalty Pharma plc's (NASDAQ:RPRX) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
Jan-29-21 11:35PM	15 Biggest IPOs of 2020 Insider Monkey
Jan-22-21 08:00AM	Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021 GlobeNewswire
Jan-19-21 08:30AM	Royalty Pharma Acquires Royalty Interest in Seltorexant From Minerva Neurosciences GlobeNewswire
08:00AM	Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million GlobeNewswire
Jan-08-21 08:05AM	Royalty Pharma increases quarterly dividend by 13% to 17 cents a share MarketWatch
08:00AM	Royalty Pharma Announces 13% Dividend Increase GlobeNewswire
Jan-07-21 04:15PM	Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12 GlobeNewswire
Dec-23-20 03:16PM	IPOs to watch in 2021: The 5 most anticipated debuts Yahoo Finance
Dec-22-20 08:30AM	Royalty Pharma Announces Charitable Gifts to Support COVID-19 Research at Leading Hospitals and Universities GlobeNewswire +5.07%
Dec-21-20 08:12AM	Royalty Pharma Announces Expansion of Leadership Team GlobeNewswire
Dec-17-20 04:29PM	Is RPRX A Good Stock To Buy Now? Insider Monkey
Dec-07-20 08:45AM	Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals GlobeNewswire
08:40AM	BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management GlobeNewswire
Dec-04-20 04:31PM	Biotech, Life Sciences IPOs Score Double-Digit Gains Barrons.com
Nov-16-20 03:39AM	Can Royalty Pharma plc's (NASDAQ:RPRX) ROE Continue To Surpass The Industry Average? Simply Wall St.
Nov-10-20 05:40PM	Royalty Pharma Reports Third Quarter 2020 Results GlobeNewswire
Nov-02-20 07:30AM	Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation GlobeNewswire
Oct-20-20 04:32PM	Royalty Pharma Announces Closing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders GlobeNewswire
Oct-19-20 09:00AM	Royalty Pharma to Announce Third-Quarter 2020 Financial Results on November 11, 2020 GlobeNewswire
Oct-15-20 11:45PM	Royalty Pharma Announces Pricing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders GlobeNewswire
09:15AM	Royalty Pharma Declares Fourth-Quarter 2020 Dividend GlobeNewswire
Oct-13-20 04:10PM	Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders GlobeNewswire
Oct-02-20 07:00AM	New Ventures Funds Rebrands as Scientia Ventures PR Newswire
Sep-16-20 11:42AM	Royalty Pharma plc (NASDAQ:RPRX) Shares Could Be 41% Below Their Intrinsic Value Estimate Simply Wall St.
Sep-02-20 04:25PM	Royalty Pharma Announces Closing of $6.0 Billion Senior Unsecured Notes GlobeNewswire
08:00AM	Royalty Pharma Declares Third-Quarter 2020 Dividend GlobeNewswire
Aug-25-20 08:14AM	Royalty Pharma prices $6 billion bond deal that is its first as a public company MarketWatch
08:00AM	Royalty Pharma Announces Pricing of $6.0 Billion Senior Unsecured Notes GlobeNewswire
Aug-19-20 09:00AM	Royalty Pharma Announces Launch of Senior Notes Offering GlobeNewswire
Aug-12-20 07:00AM	Royalty Pharma Reports Second Quarter 2020 Results GlobeNewswire
Aug-07-20 09:40AM	Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million GlobeNewswire
Aug-03-20 04:15PM	Royalty Pharma Appoints Henry A. Fernandez and Ted W. Love, M.D. to the Companys Board of Directors GlobeNewswire
Jul-20-20 04:15PM	Royalty Pharma to Announce Second-Quarter 2020 Financial Results on August 12 GlobeNewswire
07:45AM	Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics GlobeNewswire
Jul-17-20 12:00PM	7 New Stocks to Buy for 2021 and Beyond InvestorPlace
Jul-15-20 04:33PM	One Of The Biggest IPOs Of The Year Falls in Debut After Pricing High Investor's Business Daily
Jul-13-20 10:16AM	Royalty Pharmas Dazzling Debut Leads to Tepid Street Views Bloomberg -7.51%
Jul-02-20 01:02PM	Keep an Eye on Royalty Pharma Stock, 2020s Biggest IPO InvestorPlace
Jul-01-20 01:48PM	Dun & Bradstreet Trades Higher After IPO Raised $1.7 Billion Bloomberg
Jun-30-20 10:40AM	New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO PR Newswire
Jun-27-20 07:13PM	Top Insider Buys Highlight for the Week of June 26 GuruFocus.com
Jun-26-20 04:42PM	Albertsons Falters in Debut After $800 Million IPO Letdown Bloomberg
Jun-25-20 07:01PM	Cerberus-Backed Albertsons Falls Short With $800 Million IPO Bloomberg
08:43AM	New Ventures Portfolio Company, Royalty Pharma, Surges On Public Debut PR Newswire
Jun-22-20 06:10PM	What to expect from the IPO market through the end of 2020 Yahoo Finance Video
Jun-18-20 04:15PM	Royalty Pharma Announces Closing of Initial Public Offering GlobeNewswire
12:37PM	PreMarket Prep Stock Of The Day: Royalty Pharma Benzinga
09:53AM	Morning Market Stats in 5 Minutes Benzinga
Jun-17-20 09:55AM	Morning Market Stats in 5 Minutes Benzinga +9.24%
06:06AM	IPO market braces for another busy week and Royalty Pharma becomes the biggest deal year-to-date MarketWatch
Jun-16-20 06:21PM	Royalty Pharma Soars 59% After Years Biggest U.S. IPO Bloomberg
05:34PM	Nasdaq President Nelson Griggs on the 2020 IPO market Yahoo Finance Video
04:21PM	Coronavirus update: Global case tally tops 8 million and states reopen businesses even as infections and hospitalizations rise MarketWatch
03:21PM	Royalty Pharma Jumps 58% From Its IPO. Thats More Money for Drug Research. Barrons.com
12:14PM	Royalty Pharma shares soar 57.1% in market debut Reuters
12:10PM	Royalty Pharma's stock soars in public debut, as Wall Street cheers the year's largest IPO MarketWatch
09:32AM	Royalty Pharma IPO Sets Record As Largest Public Offering This Year Investor's Business Daily
07:07AM	Royalty Pharma raises $2.2 billion in biggest IPO of the year so far MarketWatch
Jun-15-20 11:29PM	Royalty Pharma IPO Expanded to Raise Almost $2.2 Billion Bloomberg
07:21PM	Royalty Pharma IPO prices at top of range in biggest 2020 U.S. listing -sources Reuters

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and 5 development-stage product candidates in various therapeutic areas, such as rare disease, oncology, neurology, infectious disease, cardiology, and diabetes. The company has royalties on various product, such as Cystic fibrosis franchise, including Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio; HIV franchise comprising Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza, and Biktarvy; Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas, and Nesina; Tysabri, Imbruvica, Xtandi, Promacta, Farxiga/Onglyza, Prevymis, Emgality, Crysvita, Erleada, IDHIFA, Trodelvy, Nurtec ODT, Tazverik, and Evrysdi; and other products, such as Bosulif, Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy, and Soliqua, as well as Tecfidera, Letairis, Lyrica, Remicade, Humira, Prezista, Rotateq, and Thalomid. Royalty Pharma plc was founded in 1996 and is based in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lloyd George W.	EVP, Investments & GC	Jul 26	Sale	39.78	13,362	531,532	595,860	Jul 27 05:29 PM
Reddoch James F.	EVP, Research & Investments	Jul 26	Sale	39.78	8,949	355,977	1,170,800	Jul 27 05:25 PM
Reddoch James F.	EVP, Research & Investments	Jul 26	Sale	39.78	8,949	355,977	1,170,800	Jul 27 05:23 PM
Reddoch James F.	EVP, Research & Investments	Jul 14	Sale	42.00	2	84	1,179,749	Jul 14 05:17 PM
Lloyd George W.	EVP, Investments & GC	Jul 13	Sale	42.01	23,049	968,252	600,773	Jul 14 05:18 PM
Reddoch James F.	EVP, Research & Investments	Jul 13	Sale	42.01	17,832	749,081	1,179,751	Jul 14 05:17 PM
Reddoch James F.	EVP, Research & Investments	Jul 12	Sale	42.04	100	4,204	1,197,583	Jul 14 05:17 PM
Lloyd George W.	EVP, Investments & GC	Jul 12	Sale	42.04	100	4,204	806,430	Jul 14 05:18 PM
Reddoch James F.	EVP, Research & Investments	Jul 08	Sale	42.05	40,655	1,709,380	1,197,683	Jul 08 07:37 PM
Lloyd George W.	EVP, Investments & GC	Jul 08	Sale	42.05	49,059	2,062,789	605,841	Jul 08 07:36 PM
Lloyd George W.	EVP, Investments & GC	Jul 07	Sale	42.01	2,900	121,828	614,233	Jul 08 07:36 PM
Reddoch James F.	EVP, Research & Investments	Jul 07	Sale	42.01	2,192	92,087	1,238,338	Jul 08 07:37 PM
Reddoch James F.	EVP, Research & Investments	Jul 06	Sale	42.40	30,270	1,283,560	1,240,530	Jul 08 07:37 PM
Lloyd George W.	EVP, Investments & GC	Jul 06	Sale	42.41	36,530	1,549,145	614,633	Jul 08 07:36 PM
RIGGS RORY B	Director	Jun 29	Sale	41.26	481,000	19,844,846	3,451,258	Jun 29 08:31 PM
RIGGS RORY B	Director	Jun 28	Sale	42.11	167,448	7,051,269	3,932,258	Jun 29 08:31 PM
RIGGS RORY B	Director	Jun 25	Sale	42.72	666,464	28,474,019	933,910	Jun 29 08:31 PM
Lloyd George W.	EVP, Investments & GC	Jun 10	Sale	46.49	70,000	3,254,369	240,000	Jun 14 06:42 PM
Lloyd George W.	EVP, Investments & GC	Jun 08	Sale	46.48	70,000	3,253,631	250,000	Jun 08 08:12 PM
Reddoch James F.	EVP, Research & Investments	Jun 08	Sale	46.43	50,000	2,321,540	1,270,800	Jun 08 08:12 PM
Reddoch James F.	EVP, Research & Investments	Jun 07	Sale	46.59	50,000	2,329,419	1,320,800	Jun 08 08:12 PM
Lloyd George W.	EVP, Investments & GC	Jun 07	Sale	46.34	122,500	5,676,228	260,000	Jun 08 08:12 PM
Urist Marshall	EVP & Co-Head of R&I	Jun 07	Sale	47.02	16,568	779,059	0	Jun 08 08:15 PM
Urist Marshall	EVP & Co-Head of R&I	Jun 04	Sale	45.13	16,566	747,662	16,568	Jun 08 08:15 PM
Lloyd George W.	EVP, Investments & GC	Jun 04	Sale	44.78	60,000	2,686,938	280,000	Jun 08 08:12 PM
Reddoch James F.	EVP, Research & Investments	Jun 04	Sale	44.60	100,000	4,459,730	1,370,800	Jun 08 08:12 PM
Urist Marshall	EVP & Co-Head Research & Inv.	Jun 02	Sale	41.52	14,566	604,850	33,134	Jun 04 06:52 PM
Reddoch James F.	EVP, Research & Investments	Jun 02	Sale	42.13	50,000	2,106,560	1,470,800	Jun 04 06:50 PM
Lloyd George W.	EVP, Investments & GC	Apr 14	Sale	42.13	69,822	2,941,920	50,000	Apr 16 05:57 PM
Reddoch James F.	EVP, Research & Investments	Apr 14	Sale	42.10	55,714	2,345,593	200,000	Apr 16 05:56 PM
Reddoch James F.	EVP, Research & Investments	Apr 12	Sale	42.32	359	15,193	255,714	Apr 14 07:51 AM
Lloyd George W.	EVP, Investments & GC	Apr 12	Sale	42.32	449	19,002	63,924	Apr 14 07:52 AM
Lloyd George W.	EVP, Investments & GC	Mar 22	Sale	46.32	54,729	2,535,226	64,013	Mar 24 05:25 PM
Reddoch James F.	EVP, Research & Investments	Mar 22	Sale	46.32	43,927	2,034,519	256,073	Mar 24 05:25 PM
Coyne Terrance P.	EVP & CFO	Mar 03	Sale	44.78	100,000	4,478,450	200,000	Mar 05 07:04 PM
Lloyd George W.	EVP, Investments & GC	Mar 02	Sale	46.94	125,000	5,867,148	75,000	Mar 04 07:03 PM
Reddoch James F.	EVP, Research & Investments	Mar 02	Sale	46.92	100,000	4,692,158	300,000	Mar 04 07:02 PM
Coyne Terrance P.	EVP & CFO	Mar 02	Sale	46.94	100,000	4,694,090	300,000	Mar 04 07:00 PM
Fernandez Henry A	Director	Feb 25	Buy	46.83	25,700	1,203,480	25,700	Feb 26 07:46 PM
ADAGE CAPITAL PARTNERS GP, L.L	10% Owner	Dec 18	Sale	44.02	101,050	4,448,221	38,714,280	Dec 18 02:36 PM
ADAGE CAPITAL PARTNERS GP, L.L	10% Owner	Dec 17	Sale	43.92	7,200,000	316,224,000	38,815,330	Dec 18 02:36 PM
RIGGS RORY B	Director	Oct 20	Sale	42.00	463,200	19,454,400	0	Oct 22 09:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience